文献速递儿童呼吸儿童心血管与肾脏

活动记录仪终点可减少儿童肺动脉高压研究样本量并促进药物研发

Actigraphy Study Endpoints to Reduce Sample Size and Facilitate Drug Development for Pediatric Pulmonary Arterial Hypertension.
PubMed 文献 · J Pediatr · 2024-11-01

这项前瞻性多中心非干预研究纳入116名儿童,评估活动记录仪测量体力活动(pA)和心率变异性(HRV)作为儿童肺动脉高压(PAH)研究终点的可行性。结果显示PAH患儿pA和HRV均显著低于健康对照,且HRV在区分Panama功能分级III与II上可能比6分钟步行距离(6MWD)更敏感;模拟显示HRV组所需样本量远小于6MWD。

要点

  • 活动记录仪在儿童PAH中可行,PAH患儿pA低约36%、HRV低约18%。
  • pA和HRV在区分Panama FC III与II上趋势优于6MWD。
  • 80%把握度下HRV每组仅需40例,6MWD需超过200例。

核心结论

  • 活动记录仪是儿童PAH可行的测量方法,pA和HRV可能比6MWD更敏感地区分Panama FC III与II,HRV可提升活动记录仪的实用性。

研究设计与样本

  • 前瞻性、多中心、非干预性研究,纳入儿童PAH患者和健康儿童,使用Actiheart和Fitbit Charge 2记录pA和心率数据,HRV定义为每日心率的标准差。

主要发现

  • 共纳入116名儿童,Actiheart和Fitbit的依从人数分别为90和98。
  • PAH患儿(n=62)较健康对照(n=54)每日pA低约36%(P < .05),每日HRV低约18%(P < .05)。
  • Panama FC III较FC II的每日pA和HRV趋势低约17%,而6MWD差异很小。
  • 80%把握度模拟显示,检测FC III与II间差异所需样本量:pA每组175例,HRV每组40例,6MWD超过最大样本量200例。

临床怎么用

  • 在儿童PAH临床研究中,可考虑将活动记录仪测量的pA和HRV作为比6MWD更敏感且需样本量更小的终点指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the feasibility of using actigraphy to measure physical activity (pA) and heart rate variability (HRV) as study endpoints in pediatric pulmonary arterial hypertension (PAH) and to compare their performance to 6-minute-walk distance (6MWD), a common primary endpoint used in PAH clinical trials in adults and children who can walk and understand the test process. STUDY DESIGN: We conducted a prospective, multicenter, noninterventional study in pediatric PAH patients and healthy children. Actiheart and Fitbit Charge 2 recorded pA and heart rate data. HRV was defined as SD of daily heart rate. Actigraphy pA and HRV and 6MWD from the same subjects were analyzed to compare children with PAH with controls, and Panama functional classification (FC) III vs II. Power/sample size simulations were conducted to detect hypothetical treatment effect equivalent to differences seen between FC III and FC II. RESULTS: We enrolled 116 children: 90 and 98 adhered with Actiheart and Fitbit, respectively. Actigraphy daily pA was ∼36% lower (P < .05) and daily HRV was ∼18% lower (P < .05) in children with PAH (n = 62) than healthy controls (n = 54). Daily pA and daily HRV trended ∼17% lower in FC III than FC II, whereas 6MWD showed little difference. Simulation at 80% power showed that pA required 175 subjects per group and HRV required 40 per group to detect the difference/effect, whereas 6MWD required over our maximum sample size of 200. CONCLUSIONS: Actigraphy is a feasible measure in pediatric PAH. Compared with 6MWD, pA and HRV may be more sensitive in differentiating Panama FC III from II. HRV may improve actigraphy's utility in pediatric PAH.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Sun H, Stockbridge N, Ivy DD, et al. Actigraphy Study Endpoints to Reduce Sample Size and Facilitate Drug Development for Pediatric Pulmonary Arterial Hypertension. J Pediatr. 2024. PMID: 39489285. doi:10.1016/j.jpeds.2024.114383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。